文献速递血栓与止血

慢性肾脏病患者中新型凝血与血小板功能检测的评估

Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease.
PubMed 文献 · J Thromb Haemost · 2022-02-03

横断面研究纳入30名健康对照和120例不同分期慢性肾脏病患者,采用旋转血栓弹力测定、多电极聚集测定、凝血酶生成试验等检测止血参数。结果发现慢性肾脏病患者存在高凝状态和血小板功能障碍,估算肾小球滤过率是独立决定因素。

要点

  • 慢性肾脏病患者D-二聚体、凝血酶-抗凝血酶复合物和ICAM-1浓度显著高于健康对照(P<.01)。
  • 旋转血栓弹力测定最大血凝块强度在慢性肾脏病患者中显著高于健康对照(P<.01)。
  • 5期慢性肾脏病患者二磷酸腺苷和凝血酶受体激活肽诱导的多电极聚集测定显著低于健康对照(P<.05),提示血小板聚集缺陷。

核心结论

  • 慢性肾脏病患者表现出旋转血栓弹力测定所测的高凝状态和多电极聚集测定所测的血小板功能障碍并存的特性,估算肾小球滤过率是血小板功能障碍和高凝状态的独立决定因素。

研究设计与样本

  • 横断面研究纳入30名健康对照和120例慢性肾脏病患者,其中2期10例、3期20例、4期20例、5期未需肾脏替代治疗20例、移植20例、新开始血液透析10例、维持血液透析20例,除标准实验室检查外还进行旋转血栓弹力测定、多电极聚集测定、凝血酶生成试验、D-二聚体及血栓形成、纤溶和内皮激活标志物检测。

主要发现

  • 慢性肾脏病患者D-二聚体、凝血酶-抗凝血酶复合物和ICAM-1浓度显著高于健康对照(P<.01)。
  • 旋转血栓弹力测定最大血凝块强度在慢性肾脏病患者中显著高于健康对照(P<.01)。
  • 5期慢性肾脏病患者(透析前和新开始血液透析)二磷酸腺苷和凝血酶受体激活肽诱导的多电极聚集测定显著低于健康对照(P<.05),提示血小板聚集缺陷。
  • 内源性凝血酶潜力和凝血酶峰值在各组间无统计学差异,但5期慢性肾脏病患者较健康对照 lag time 延长(7.91 vs. 6.33,P<.001)、凝血酶峰值时间延长(10.8 vs. 9.5,P<.05)。
  • 多因素分析证实估算肾小球滤过率对旋转血栓弹力测定和多电极聚集测定变异的直接影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemostasis evaluation in chronic kidney disease (CKD) is critical for optimal management of thrombotic and bleeding events. Standard coagulation screens are inadequate for predicting coagulopathy in CKD. OBJECTIVE: To evaluate hemostasis parameters in patients with different stages of CKD using novel coagulation assays. PATIENTS/METHODS: Cross-sectional study of 30 healthy controls (HC) and 120 CKD patients (10 Stage 2, 20 Stage 3, 20 Stage 4, 20 Stage 5 not requiring renal replacement therapy, 20 transplant, 10 newly started on hemodialysis [HD], 20 established on HD). Standard laboratory tests were performed in addition to rotational thromboelastometry (ROTEM), multiple electrode aggregometry (MEA), thrombin generation assays, D-dimer, and markers of thrombogenesis (thrombin-antithrombin [TAT]), fibrinolysis, and endothelial activation (intercellular adhesion molecule-1 [ICAM-1]). RESULTS: D-dimer, TAT, and ICAM-1 concentrations were significantly higher in patients with CKD than HC (P < .01). ROTEM maximum clot firmness was significantly higher in patients than in HC (P < .01). In CKD Stage 5 patients (pre-HD and started HD) adenosine diphosphate and thrombin receptor activating peptide MEA tests were significantly lower than HC indicating platelet aggregation defect (P < .05). Multivariate analysis confirmed the direct effect of estimated glomerular filtration rate (eGFR) in the variance of ROTEM and MEA tests. Endogenous thrombin potential and peak thrombin were not statistically different between groups, but Stage 5 CKD patients had prolonged lag time (7.91 vs. 6.33, P < .001) and time to thrombin peak (10.8 vs. 9.5, P < .05) compared to HC. CONCLUSIONS: Patients with CKD exhibit features of concomitant hypercoagulability measured by ROTEM and platelet dysfunction measured with MEA. eGFR was an independent determinant of platelet dysfunction and hypercoagulability.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Abdelmaguid A, Roberts LN, Tugores L, et al. Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease. J Thromb Haemost. 2022. PMID: 35068080. doi:10.1111/jth.15653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。